AIM Immunotech Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2025 Annual Meeting of Stockholders held on December 16, 2025. The Company, AIM Immunotech Inc., is incorporated in Delaware and trades on the NYSE American under the symbol AIM. As of the record date, there were 2,764,188 shares of common stock outstanding. A quorum was present with 1,144,383 shares (41.4%) represented.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
- Proposal 1 (Election of Directors): All five nominees were elected. Significant broker non-votes (833,173 shares) were recorded for each nominee.
- Proposal 2 (Ratification of Auditors): Approved. BDO USA, P.C. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Proposal 3 (Executive Compensation): Not Approved as a formal matter. While a majority of votes cast (193,668 For vs. 115,337 Against) favored the compensation, the proposal failed to receive the affirmative vote of a majority of the voting power represented at the meeting due to 833,173 broker non-votes.
- Proposal 4 (Frequency of Compensation Votes): Shareholders voted to hold advisory votes on executive compensation annually (284,856 votes for 1 Year).
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future operations. The primary risk highlighted is the failure of the executive compensation proposal to meet the specific voting threshold required for formal approval, despite majority support among votes cast.
Investor Verification Checklist
- Verify the Company's response to the failed executive compensation vote (Proposal 3) in subsequent filings or press releases.
- Confirm the impact of the high volume of broker non-votes on future corporate governance proposals.
- Review the definitive proxy statement filed on November 4, 2025, for detailed background on the director nominees and auditor selection.